AstraZeneca Receives China Approval for Rare Pediatric Disease Treatment
AstraZeneca's drug Koselugo (selumetinib) has been approved in China for the treatment of children with neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibromas.
AstraZeneca has received approval from China's National Medical Products Administration (NMPA) for its medication Koselugo (selumetinib). The approval targets the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in pediatric patients with neurofibromatosis type 1 (NF1), aged three years and older.
NF1 is a rare genetic condition affecting approximately one in 3,000 individuals globally. It is characterized by the development of benign tumors along nerves. In 30-50% of patients, these tumors can lead to significant functional impairment, pain, and disfigurement, substantially impacting a child's quality of life.
The approval is based on positive outcomes from the SPRINT Stratum 1 trial. The study demonstrated that Koselugo reduced the size of inoperable tumors in pediatric patients. The drug is an oral treatment that targets the underlying mechanism of tumor growth by inhibiting MEK enzymes.
Koselugo is already approved for treatment in the United States, the European Union, Japan, and several other countries. This Chinese approval expands treatment options for NF1 patients in a region where therapeutic choices for rare diseases have historically been limited.